Life Sciences and Energy

Irish med-tech company gains international recognition at Hong Kong award ceremony

By Business & Finance
25 March 2014

Aerogen, an Irish headquartered medical technology and drug delivery product innovator, has been selected as ‘Best Company for Innovation and Leadership’ at the 2014 IAIR Global Awards in Hong Kong.

The recognition comes just two years after Aerogen introduced its multi-award winning range of Aeroneb® nebulizer products into China targeting high performance aerosol drug delivery in the respiratory market.

In that short period of time annual sales in China have grown year on year and are expected to reach €5m in next three years as the company rolls out its Aeroneb® Solo product line.

All products are based on Aerogen’s patented vibrating mesh technology which creates a fine particle aerosol for targeted drug delivery to the lungs and are used to treat a broad spectrum of patient respiratory conditions and to deliver medication in intensive care settings.

Accepting the award, Jim Liu, regional manager, Greater China at Aerogen, said: “In two short years, Aerogen has worked with our independent distribution partners Beijing Aeonmed Co. Ltd and Xiamen Galemed Corporation to roll out our products to Intensive Care Units and homes across mainland China. There is an increasing demand for our high performance hospital grade products and we are delighted to be recognised for our innovation and leadership in this new market.”

John Power, Aerogen CEO added: “Aerogen is honoured to receive the IAIR award for Innovation and Leadership. After many years of ground-breaking research and development Aerogen successfully pioneered the delivery of high performance aerosol drug to the ventilated patient. We see Innovation and IP as the very core of our business and our proprietary vibrating mesh technology, which we have protected globally by numerous International patents, has enabled Aerogen to become the recognised gold-standard for targeted drug delivery in our field.

“Our initial move into China reflected its position as an emergent high-growth market for advanced technologies and we intend to rapidly establish in China a first class technical and clinical product support infrastructure for both our independent distributors and our multi-national respiratory healthcare partners such as Philips, Covidien, GE-Healthcare and Maquet. We were delighted to receive approval from the State Food and Drug Administration for our products and look forwarding to introducing the Aeroneb® Solo which has special application in pediatric intensive care. In addition to being recognised for our leadership in the market, it is also rewarding that Chinese patients are able to enjoy the benefits experienced by other users of our products throughout the globe.”

Aerogen received its award at the 4th annual IAIR Global Awards. Previous recipients of the awards include China Telecom, Johnson & Johnson, Nestlé, IBM, Samsung and Novartis.